Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

Fangzhou Inc. (HKEX: 06086), a leading AI-driven Internet healthcare provider, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its platform in collaboration with Novo Nordisk. The launch leverages Fangzhou's AI-enabled chronic disease management ecosystem to improve patient access to innovative diabetes treatments in China, the world's largest diabetes market with approximately 148 million adults living with diabetes.